-$0.09 Earnings Per Share Expected for Curis, Inc. (NASDAQ:CRIS) This Quarter

Analysts forecast that Curis, Inc. (NASDAQ:CRIS) will post earnings of ($0.09) per share for the current quarter, Zacks reports. Two analysts have made estimates for Curis’ earnings. Curis reported earnings per share of ($0.28) during the same quarter last year, which suggests a positive year over year growth rate of 67.9%. The business is scheduled to report its next earnings report on Tuesday, May 11th.

On average, analysts expect that Curis will report full year earnings of ($0.41) per share for the current year, with EPS estimates ranging from ($0.52) to ($0.35). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.43) per share, with EPS estimates ranging from ($0.45) to ($0.41). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Curis.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Monday, March 15th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). The firm had revenue of $3.02 million for the quarter, compared to analyst estimates of $2.74 million. During the same quarter in the previous year, the business earned ($0.22) earnings per share.

A number of research firms have recently weighed in on CRIS. Zacks Investment Research downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Friday, March 19th. HC Wainwright upped their price target on shares of Curis from $9.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, January 15th. TheStreet raised shares of Curis from a “d-” rating to a “c-” rating in a research note on Tuesday, March 23rd. B. Riley began coverage on shares of Curis in a research note on Tuesday, March 30th. They issued a “buy” rating and a $19.00 price target on the stock. Finally, Jonestrading increased their target price on shares of Curis from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, March 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Curis presently has an average rating of “Buy” and an average target price of $14.17.

In other Curis news, CEO James E. Dentzer sold 2,283 shares of the stock in a transaction on Monday, January 25th. The shares were sold at an average price of $10.96, for a total transaction of $25,021.68. Following the transaction, the chief executive officer now directly owns 70,362 shares of the company’s stock, valued at $771,167.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.34% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. bought a new stake in Curis during the first quarter valued at about $49,000. Captrust Financial Advisors bought a new stake in Curis during the fourth quarter valued at about $41,000. Lindbrook Capital LLC bought a new stake in Curis during the fourth quarter valued at about $57,000. Blair William & Co. IL bought a new stake in Curis during the fourth quarter valued at about $82,000. Finally, SG Americas Securities LLC bought a new stake in Curis during the fourth quarter valued at about $85,000. Institutional investors own 34.66% of the company’s stock.

Shares of NASDAQ CRIS traded up $0.18 during mid-day trading on Friday, reaching $10.55. The company had a trading volume of 28,921 shares, compared to its average volume of 2,096,951. Curis has a twelve month low of $0.69 and a twelve month high of $13.44. The stock has a market capitalization of $965.53 million, a PE ratio of -13.10 and a beta of 3.29. The stock’s 50 day moving average is $11.09 and its 200-day moving average is $7.28.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation that is in Phase Ia/Ib clinical trial in patients with solid tumors.

Read More: Market Capitalization – What it Means for Investors

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.